MedPath
Found 10 clinical trials|View Analysis
Sort by:

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

Not Applicable
Conditions
Progesterone Receptor Negative
Progressive Disease
Stage IIA Rectal Cancer
Stage IIB Rectal Cancer
Stage III Non-Small Cell Lung Cancer
Head and Neck Carcinoma
Limited Stage Small Cell Lung Carcinoma
Myelodysplastic Syndrome
Stage II Pancreatic Cancer
Stage IIA Pancreatic Cancer
Interventions
Other: Best Practice
Other: Laboratory Biomarker Analysis
Procedure: Supportive Care
Other: Survey Administration
First Posted Date
2017-05-16
Last Posted Date
2022-02-03
Lead Sponsor
Stanford University
Target Recruit Count
128
Registration Number
NCT03154190
Locations
🇺🇸

Virginia K Crosson Cancer Center, Fullerton, California, United States

Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Stage IIB-IIIC Esophageal Cancer

Early Phase 1
Withdrawn
Conditions
Stage IIIA Esophageal Cancer AJCC v7
Stage IIB Esophageal Cancer AJCC v7
Stage III Esophageal Cancer AJCC v7
Stage IIIB Esophageal Cancer AJCC v7
Stage IIIC Esophageal Cancer AJCC v7
Interventions
Drug: Ferumoxytol
Procedure: Magnetic Resonance Imaging
First Posted Date
2016-08-05
Last Posted Date
2021-09-16
Lead Sponsor
OHSU Knight Cancer Institute
Registration Number
NCT02857218

Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer

Phase 1
Completed
Conditions
Stage IIB Esophageal Cancer AJCC v7
Stage IIIA Esophageal Cancer AJCC v7
Malignant Neoplasm of the Cervical Esophagus
Malignant Neoplasm of the Thoracic Esophagus
Stage IIA Esophageal Cancer AJCC v7
Stage IIIC Esophageal Cancer AJCC v7
Gastroesophageal Junction Adenocarcinoma
Stage IIIB Esophageal Cancer AJCC v7
Interventions
First Posted Date
2015-03-17
Last Posted Date
2019-07-24
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
3
Registration Number
NCT02389751
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy

Phase 1
Active, not recruiting
Conditions
Advanced Bile Duct Carcinoma
Stage IIB Pancreatic Cancer AJCC v6 and v7
Stage II Esophageal Cancer AJCC v7
Stage II Pancreatic Cancer AJCC v6 and v7
Stage IIA Esophageal Cancer AJCC v7
Stage IIA Pancreatic Cancer AJCC v6 and v7
Stage IIB Esophageal Cancer AJCC v7
Stage III Colon Cancer AJCC v7
Stage III Gastric Cancer AJCC v7
Stage III Liver Cancer
Interventions
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Ropidoxuridine
First Posted Date
2015-03-06
Last Posted Date
2024-03-07
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
19
Registration Number
NCT02381561
Locations
🇺🇸

Rhode Island Hospital, Providence, Rhode Island, United States

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

Phase 1
Withdrawn
Conditions
Stage IIIA Esophageal Cancer
Stage IIIA Gastric Cancer
Stage IIIB Esophageal Cancer
Stage IIIB Gastric Cancer
Adenocarcinoma of the Esophagus
Intestinal Adenocarcinoma of the Stomach
Adenocarcinoma of the Gastroesophageal Junction
Mixed Adenocarcinoma of the Stomach
Stage IIIC Esophageal Cancer
Stage IIIC Gastric Cancer
Interventions
Drug: c-Met inhibitor AMG 337
Other: placebo
Drug: oxaliplatin
Drug: leucovorin calcium
Drug: fluorouracil
Other: pharmacological study
Other: laboratory biomarker analysis
First Posted Date
2015-01-26
Last Posted Date
2023-05-25
Lead Sponsor
Eastern Cooperative Oncology Group
Registration Number
NCT02344810
Locations
🇺🇸

ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma

Phase 2
Active, not recruiting
Conditions
Adenocarcinoma of the Esophagus
Adenocarcinoma of the Gastroesophageal Junction
Stage IIIC Esophageal Cancer
Adenocarcinoma of the Gastric Cardia
Stage IIIA Esophageal Cancer
Stage IIIB Esophageal Cancer
Interventions
Drug: oxaliplatin
Drug: leucovorin calcium
Drug: fluorouracil
Procedure: therapeutic conventional surgery
Radiation: radiation therapy
Drug: carboplatin
Drug: paclitaxel
First Posted Date
2014-01-15
Last Posted Date
2024-01-08
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
63
Registration Number
NCT02037048
Locations
🇺🇸

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Phase 1
Terminated
Conditions
Adenocarcinoma of the Gastroesophageal Junction
HER2-positive Breast Cancer
Male Breast Cancer
Recurrent Breast Cancer
Recurrent Esophageal Cancer
Recurrent Gastric Cancer
Stage IIIC Breast Cancer
Stage IIIC Esophageal Cancer
Stage IIIC Gastric Cancer
Stage IV Breast Cancer
Interventions
Drug: Akt inhibitor MK2206
Biological: trastuzumab
Drug: lapatinib ditosylate
Other: laboratory biomarker analysis
First Posted Date
2012-10-12
Last Posted Date
2013-09-30
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
60
Registration Number
NCT01705340
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery

Phase 2
Completed
Conditions
Adenocarcinoma of the Esophagus
Adenocarcinoma of the Gastroesophageal Junction
Diffuse Adenocarcinoma of the Stomach
Intestinal Adenocarcinoma of the Stomach
Mixed Adenocarcinoma of the Stomach
Recurrent Esophageal Cancer
Recurrent Gastric Cancer
Squamous Cell Carcinoma of the Esophagus
Stage IIIB Esophageal Cancer
Stage IIIB Gastric Cancer
Interventions
Drug: cyclodextrin-based polymer-camptothecin CRLX101
Other: Laboratory biomarker analysis
Other: Pharmacological studies
First Posted Date
2012-06-06
Last Posted Date
2018-02-01
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
10
Registration Number
NCT01612546
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Phase 1
Completed
Conditions
Recurrent Esophageal Carcinoma
Anaplastic Astrocytoma
Anaplastic Oligoastrocytoma
Anaplastic Oligodendroglioma
Estrogen Receptor Negative
Estrogen Receptor Positive
Glioblastoma
Hormone-Resistant Prostate Cancer
Metastatic Prostate Carcinoma
Metastatic Renal Cell Cancer
Interventions
Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Sirolimus
First Posted Date
2012-02-01
Last Posted Date
2016-10-04
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
18
Registration Number
NCT01522820
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer

Phase 2
Completed
Conditions
Adenocarcinoma of the Esophagus
Adenocarcinoma of the Gastroesophageal Junction
Diffuse Adenocarcinoma of the Stomach
Stage IA Esophageal Cancer
Stage IA Gastric Cancer
Stage IB Esophageal Cancer
Stage IIB Gastric Cancer
Squamous Cell Carcinoma of the Esophagus
Stage IIA Gastric Cancer
Stage IIIA Gastric Cancer
Interventions
Biological: bevacizumab
Drug: oxaliplatin
Drug: leucovorin calcium
Drug: fluorouracil
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis
First Posted Date
2010-10-01
Last Posted Date
2022-09-07
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
20
Registration Number
NCT01212822
Locations
🇺🇸

University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

Case Western Reserve University, Cleveland, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath